BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for North American Extreme

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $4354.20.64 only $1741.68

ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.58
0.00%
US Tech 100
20,313.20
-0.29%
S&P 500
6,021.63
0.57%
US Dollar vs CAD
1.40539
0.00%
Bitcoin
93,270.62
1.41%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Verve Therapeutics Inc (VERV)

  7. Verve Therapeutics Inc (VERV) News

Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

Verbund Ag
Verbund Ag
Verbund Ag
Verbund Ag
5.31
0.02
(0.38%)
Closed November 26 3:00PM
Delayed by 15 minutes
5.31
0.00
( 0.00% )
Pre Market: 5:59AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

VERV News

Official News Only

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 08 2024
VERV (0.38%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 05 2024
VERV (0.38%)

Form 8-K - Current report
Edgar (US Regulatory)
November 05 2024
VERV (0.38%)

VERV Discussion

View Posts
Monksdream Monksdream 3 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 3 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 4 months ago
VERV 10Q due AUGUST5
👍️0
Monksdream Monksdream 5 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 5 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 6 months ago
VERV more new lows up ahead
👍️0
Monksdream Monksdream 6 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 week low
👍️0
Monksdream Monksdream 7 months ago
VERV new 52 lo
👍️0
Firestorm22 Firestorm22 8 months ago
uh oh
👍️0
Monksdream Monksdream 8 months ago
VERV over $10
👍️0
fink fink 9 months ago
Looking for an entry now
👍️0
Terpi Terpi 1 year ago
Could see another nice move here is the 50 day holds into close.
👍️0
Monksdream Monksdream 1 year ago
VERV morning rally
👍️0
TheFinalCD TheFinalCD 2 years ago
https://cathiesark.com/
👍️0
crudeoil24 crudeoil24 2 years ago
VERV IS A GREAT $$$$$ OPPORTUNITY.
👍️0
crudeoil24 crudeoil24 2 years ago
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
👍️0
crudeoil24 crudeoil24 2 years ago
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
👍️0

Your Recent History

NASDAQ
VERV
Verve Therapeutics
BOV
A1TH34
Autohome
BIT
P1OP72
BNP Paribas Issuance
BIT
P1DBE5
BNP Paribas Issuance
BIT
P15Y33
BNP Paribas Issuance
BOV
SOND6F
SONDOTECNICA PNB
BIT
P1K5I1
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for North American Extreme

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $4354.20.64 only $1741.68